Sherlock Biosciences Releases Clinical Data from Dartmouth-Hitchcock Health's Pilot Study of Sherlock CRISPR SARS-CoV-2 Kit
1 September 2020 - - US-based engineering biology company Sherlock Biosciences has reported data from a 20 clinical sample pilot study conducted by Gregory J. Tsongalis, Ph.D., and his team at Dartmouth-Hitchcock Medical Center in Lebanon, NH.

The study evaluated the accuracy and performance of the Sherlock CRISPR SARS-CoV-2 kit for the detection of nucleic acid from the novel coronavirus that causes COVID-19. Sherlock test results were 100 % concordant with results from Dartmouth-Hitchcock's lab-based polymerase chain reaction test method.

The Sherlock CRISPR SARS-CoV-2 test kit is designed for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988, 42 USC. §263a, to perform high complexity tests.

The kit, for which Sherlock Biosciences recently received Emergency Use Authorization by the US Food and Drug Administration, is based on the Sherlock method, which stands for Specific High sensitivity Enzymatic Reporter unLOCKing.

The Sherlock CRISPR collateral detection reaction identified SARS-CoV-2 across a range of viral loads with high accuracy in previously tested patient samples.

Sherlock Biosciences is dedicated to making molecular diagnostics better, faster and more affordable through Engineering Biology platforms.

The company is developing applications of Sherlock, a CRISPR-based method to detect and quantify specific genetic sequences, and Inspectr, a Synthetic Biology-based molecular diagnostics platform that is instrument-free.

Sherlock and Inspectr can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests, and disease detection in the field.

In May 2020, the company received Emergency Use Authorization from the US Food and Drug Administration for its Sherlock CRISPR SARS-CoV-2 kit, the first FDA-authorized use of CRISPR technology.

Dartmouth-Hitchcock Health, New Hampshire's only academic health system and the state's largest private employer, serves a population of 1.9 m across Northern New England.

D-HH provides access to more than 2,400 providers in almost every area of medicine, delivering care at its flagship hospital, Dartmouth-Hitchcock Medical Center in Lebanon, NH.

DHMC was named again in 2020 as the #1 hospital in New Hampshire by US News and World Report, and recognized for high performance in 9 clinical specialties and procedures.

Dartmouth-Hitchcock Health also includes the Norris Cotton Cancer Center, one of only 51 NCI-designated Comprehensive Cancer Centers in the nation; the Children's Hospital at Dartmouth-Hitchcock, the state's only children's hospital; affiliated member hospitals in Lebanon, Keene, and New London, NH, and Windsor, VT, and Visiting Nurse and Hospice for Vermont and New Hampshire; and 24 Dartmouth-Hitchcock clinics that provide ambulatory services across New Hampshire and Vermont.

The D-H system trains nearly 400 residents and fellows annually, and performs world-class research, in partnership with the Geisel School of Medicine at Dartmouth and the White River Junction VA Medical Center in White River Junction, VT.